We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
-0.84%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$5.11M
(-2.1%)
Cap. Flow
+$8.26M
Cap. Flow
% of AUM
3.42%
Top 10 Holdings %
Top 10 Hldgs %
57.4%
Holding
86
New
15
Increased
42
Reduced
10
Closed
17
Avg Time Held Equity + Options
2.7
quarters
Top 10 Avg Time Held Equity + Options
0.9
quarters
Top 20 Avg Time Held Equity + Options
2.2
quarters
Avg Time Held Equity only
2.8
quarters
Top 10 Avg Time Held Equity only
0.9
quarters
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$7.21M |
| 2 |
Intra-Cellular Therapies Inc.
ITCI
|
+$5.91M |
| 3 |
Veracyte
VCYT
|
+$5.84M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$4.65M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$3.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$5.42M |
| 2 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.38M |
| 3 |
Immunogen Inc
IMGN
|
+$4.81M |
| 4 |
Halozyme
HALO
|
+$2.85M |
| 5 |
Cytokinetics
CYTK
|
+$2.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.52% |
| 2 | Miscellaneous | 12.62% |
| 3 | Financials | 1.28% |
| 4 | Industrials | 0.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
LeonaBio Inc
LONA
$58.1M
| $27M | 11.16% |
+1,000
| New | +$105K |
2022 Q1
0 quarters
|
|
2
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.77B
| $27M | 11.16% |
300,000
+100,000
| +50% | +$9.23M |
2021 Q4
1 quarter
|
|
|
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $18.9M | 7.82% |
308,819
+113,819
| +58% | +$5.91M |
2020 Q4
5 quarters
|
|
|
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $14.2M | 5.88% |
443,381
+251,336
| +131% | +$7.21M |
2020 Q4
5 quarters
|
|
|
5
Veracyte
VCYT
$3.52B
| $11.7M | 4.86% |
425,554
+204,192
| +92% | +$5.84M |
2021 Q1
4 quarters
|
|
|
CTIC
6
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $10.5M | 4.35% |
2,250,000
+766,171
| +52% | +$2.29M |
2021 Q4
1 quarter
|
|
7
DELISTED
Merus
MRUS
| $8.59M | 3.55% |
324,719
+4,545
| +1% | +$122K |
2021 Q1
4 quarters
|
|
8
Cerus
CERS
$453M
| $7.68M | 3.18% |
1,398,400
+355,678
| +34% | +$1.97M |
2021 Q2
3 quarters
|
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.1M | 2.94% |
67,442
+5,742
| +9% | +$560K |
2020 Q4
5 quarters
|
|
|
APEN
10
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.08M | 2.51% |
1,004,399
+264,795
| +36% | +$1.61M |
2021 Q4
1 quarter
|
|
|
11
DELISTED
Apellis Pharmaceuticals
APLS
| $5.35M | 2.22% |
+105,368
| New | +$4.65M |
2022 Q1
0 quarters
|
|
12
Aclaris Therapeutics
ACRS
$503M
| $4.75M | 1.96% |
275,333
-10,893
| -4% | -$149K |
2021 Q1
4 quarters
|
|
13
DELISTED
iTeos Therapeutics
ITOS
| $4.47M | 1.85% |
138,843
+837
| +0.6% | +$30.4K |
2021 Q2
3 quarters
|
|
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.36M | 1.8% |
102,497
+22,149
| +28% | +$2.76M |
2020 Q4
5 quarters
|
|
15
Cogent Biosciences
COGT
$4.97B
| $4.3M | 1.78% |
573,699
-277,236
| -33% | -$1.93M |
2020 Q4
5 quarters
|
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.79M | 1.57% |
46,122
-14,635
| -24% | -$1.5M |
2020 Q4
5 quarters
|
|
17
Immatics
IMTX
$1.09B
| $3.56M | 1.47% |
445,334
+54,179
| +14% | +$494K |
2021 Q1
4 quarters
|
|
18
Krystal Biotech
KRYS
$9.75B
| $3.09M | 1.28% |
46,489
-181
| -0.4% | -$11.3K |
2021 Q4
1 quarter
|
|
|
19
DELISTED
Immunogen Inc
IMGN
| $3.07M | 1.27% |
645,000
-869,411
| -57% | -$4.81M |
2020 Q4
5 quarters
|
|
|
NGM
20
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $3.06M | 1.27% |
+200,494
| New | +$3.13M |
2022 Q1
0 quarters
|
|
|
OTIC
21
DELISTED
Otonomy, Inc.
OTIC
| $2.9M | 1.2% |
1,207,385
+7,571
| +0.6% | +$16.1K |
2020 Q4
5 quarters
|
|
22
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $2.76M | 1.14% |
68,709
+1,269
| +2% | +$53.1K |
2020 Q4
5 quarters
|
|
23
United Therapeutics
UTHR
$23.3B
| $2.66M | 1.1% |
14,836
+285
| +2% | +$54.3K |
2020 Q4
5 quarters
|
|
|
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $2.54M | 1.05% |
41,002
-87,899
| -68% | -$5.38M |
2021 Q4
1 quarter
|
|
25
DELISTED
Crinetics Pharmaceuticals
CRNX
| $2.5M | 1.04% |
114,004
+2,144
| +2% | +$43.4K |
2021 Q3
2 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Silverarc Capital Management held 86 positions worth $242M, down 2.1% from $247M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Silverarc Capital Management deployed $8.26M of net new capital in Q1 2022, opening 15 new positions and adding to 42 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 105,368 shares worth $5.35M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.38M trimmed.
- Silverarc Capital Management's largest Q1 2022 buy was Apellis Pharmaceuticals: 105,368 shares worth $5.35M.
- Silverarc Capital Management added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $7.21M increase.
- Silverarc Capital Management's biggest Q1 2022 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.38M.
- Silverarc Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $5.42M.
- Silverarc Capital Management's ten largest holdings make up 57% of its $242M portfolio in Q1 2022.
- Silverarc Capital Management opened 15 new positions and closed 17 in Q1 2022.
- Silverarc Capital Management's portfolio value fell 2.1% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.